Schäfer, Stefan <br/><br/>
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.  [electronic resource] 

 -  Cardiovascular research  Apr 2009 
 - 30-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1755-3245 
<br/><br/><label>Standard No.: </label>10.1093/cvr/cvp002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Blood Pressure--drug effects<br/>Cyclic GMP--blood<br/>Cyclic Nucleotide Phosphodiesterases, Type 5--metabolism<br/>Disease Models, Animal<br/>Fibrillar Collagens--metabolism<br/>Fibrosis<br/>Hemodynamics--drug effects<br/>Hypertension, Pulmonary--chemically induced<br/>Hypertrophy, Right Ventricular--enzymology<br/>Male<br/>Monocrotaline<br/>Myocardium--enzymology<br/>Natriuretic Peptides--metabolism<br/>Osteopontin--metabolism<br/>Phosphodiesterase 5 Inhibitors<br/>Phosphodiesterase Inhibitors--administration & dosage<br/>Piperazines--administration & dosage<br/>Pulmonary Artery--surgery<br/>Purines--administration & dosage<br/>RNA, Messenger--metabolism<br/>Rats<br/>Rats, Sprague-Dawley<br/>Rats, Wistar<br/>Sildenafil Citrate<br/>Stroke Volume--drug effects<br/>Sulfones--administration & dosage<br/>Time Factors<br/>Tissue Inhibitor of Metalloproteinase-1--metabolism<br/>Ventricular Pressure--drug effects<br/>Ventricular Remodeling--drug effects